Earnings summaries and quarterly performance for Silence Therapeutics.
Executive leadership at Silence Therapeutics.
Board of directors at Silence Therapeutics.
Research analysts who have asked questions during Silence Therapeutics earnings calls.
JL
Jin Law
Goldman Sachs
4 questions for SLN
Also covers: MLYS
KB
Konstantinos Biliouris
BMO Capital Markets
4 questions for SLN
Also covers: ALNY, BEAM, BMRN +3 more
MM
Myles Minter
William Blair & Company
4 questions for SLN
Also covers: ALEC, ARCT, ARGX +11 more
MU
Michael Ulz
Morgan Stanley
3 questions for SLN
Also covers: ALNY, ARWR, FATE +8 more
Kostas Biliouris
BMO Capital Markets
1 question for SLN
Also covers: ALNY, BMRN, LEGN +2 more
Patrick Trucchio
H.C. Wainwright & Co.
1 question for SLN
Also covers: ALT, ARWR, ATAI +13 more
Recent press releases and 8-K filings for SLN.
Silence Therapeutics Announces Leadership Changes
SLN
CEO Change
Management Change
Board Change
- Craig Tooman, who served as President, Chief Executive Officer, and Board member since 2022, ended his employment with Silence Therapeutics plc and stepped down from the Board effective December 14, 2025, by mutual consent.
- Iain Ross, Chairman of the Silence Board, was appointed as interim principal executive officer of the Company, effective immediately.
- James Ede-Golightly was re-appointed to the Company's Board of Directors, effective immediately. He previously served on the Board from April 2019 to June 26, 2025.
Dec 15, 2025, 9:01 PM
Silence Therapeutics Provides Update on Clinical Programs and Financial Position
SLN
New Projects/Investments
Guidance Update
- Silence Therapeutics' lead compound, SLN360 for Lp(a), is Phase III ready and awaiting a partnership for its cardiovascular outcome trial. The company has demonstrated up to 98%-99% suppression of Lp(a) in Phase II.
- The SLN124 program for polycythemia vera (PV) is currently in Phase II, with results expected in the early third quarter of 2026. Phase I data showed robust results, including sustained hematocrit below 45% and reduced need for phlebotomy.
- The company reported a cash position of approximately $102 million as of September 30, 2025, which is projected to fund current activities into 2028.
- A third program, developed in partnership with AstraZeneca, is currently in Phase I.
Nov 19, 2025, 1:00 PM
Silence Therapeutics Provides Update on Clinical Programs and Financials
SLN
New Projects/Investments
Guidance Update
- Silence Therapeutics is advancing SLN124 for polycythemia vera (PV) in Phase 2, with results expected in early Q3 2026, following strong Phase 1 data demonstrating reduced phlebotomy need and sustained hematocrit control.
- Its lead compound, SLN360 for Lp(a), is phase three ready and awaiting a partnership to proceed with a cardiovascular outcome trial, having demonstrated up to 98-99% Lp(a) suppression in earlier trials.
- The company reported a cash position of $102 million as of September 30, 2025, providing a runway into 2028.
- Key upcoming industry milestones in 2026 include results from Novartis and Amgen's Lp(a) cardiovascular outcome trials, which could significantly impact the market for SLN360.
Nov 19, 2025, 1:00 PM
Silence Therapeutics plc Reports Q3 2025 Financial Results and Business Highlights
SLN
Earnings
New Projects/Investments
Guidance Update
- Silence Therapeutics plc announced its financial results for the third quarter ended September 30, 2025.
- The company reported a net loss of $21.0 million for Q3 2025, compared to a $35.5 million net loss for Q3 2024.
- As of September 30, 2025, cash and cash equivalents, and short-term investments totaled $102.2 million, which is expected to fund operational plans into 2028.
- The SANRECO Phase 2 study of divesiran for polycythemia vera (PV) has achieved full enrollment, with initial topline results anticipated in 3Q 2026.
Nov 6, 2025, 12:38 PM
Quarterly earnings call transcripts for Silence Therapeutics.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more